Clinical Trial Update: First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating first-line FOLFOX-bevacizumab in advanced colorectal cancer with wild-type Ras; study terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFOX + Bevacizumab

Snippet

Sponsor: Brown University | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-11-04